Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.
“We need to identify those patients with high-grade T1 bladder cancer that are likely to recur or progress… and find additional options to prevent recurrence and progression in these patients,” said Joaquim Bellmunt, MD, PhD, in a presentation at the SUO annual meeting.
Read highlights from a presentation by Toni K. Choueiri, MD, at the Society of Urologic Oncology annual meeting.
Other products discussed include a stent system for treating ureteral obstructions, a male infertility test, and more.
Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
The genomic profiling tool distinguishes among the dominant three malignant and one benign renal cancer subtypes.
Two late-stage immunotherapy drugs for the treatment of urothelial carcinoma reach regulatory, research milestones.
A team from Roswell Park Cancer Institute has developed and validated a quality assessment tool based on prospectively collected data on robot-assisted cystectomy.
Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
A recently approved treatment for urothelial carcinoma provides durable responses when used as first-line treatment in patients who are ineligible for cisplatin-based therapy, according to a recent study.
A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.
A recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.
Results from a recent prospective trial suggest that active surveillance may be suitable for some patients with advanced renal cell carcinoma.
In her latest blog post, Adele M. Caruso, MSN, CRNP, discusses challenges related to bladder cancer surveillance and how they can be overcome.
Once-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Among survivors of the most common types of cancer, bladder cancer survivors have the highest risk for developing a second primary cancer, according to a recent study.
Other products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more.
The emergence of robot-assisted laparoscopic donor nephrectomy (RLDN) and new findings regarding renal transplant patients' cancer risk highlight the discussions of transplantation/vascular surgery discussions at this year's AUA meeting.
Multiple studies on exosomes, data from the IMvigor 210 trial of atezolizumab (TECENTRIQ), and research on prehabilitation for cystectomy were among the highlights in bladder cancer from the 2016 AUA annual meeting.
Other products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.
A recently released guideline on diagnosis and treatment of nonmuscle-invasive bladder cancer from the AUA and the Society of Urologic Oncology provides practitioners with a risk-stratified clinical framework to aid treatment decisions and surveillance strategies, said Sam S. Chang, MD, MBA.
Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
Research on the use of a CO2 laser for penile carcinoma in situ and FDG positron positron emission tomography-computed tomography in identifying inguinal nodal metastasis (with clinically node negative groins) during monitoring after primary treatment for penile squamous cell carcinoma were among key abstracts in the area of penile, testis, and urethral cancer.
Other kidney cancer research included an 8-gene panel that was able to predict high tumor grade in biopsy specimens and a review of perioperative transfusion’s effect on recurrence-free and overall survival.
